WO2026094020 - PHTHALIC ACID AND VANILLIC ACID BASED CATIONIC LIPIDS
National phase entry is expected:
Publication Number
WO/2026/094020
Publication Date
07.05.2026
International Application No.
PCT/IB2025/061236
International Filing Date
04.11.2025
Title **
[English]
PHTHALIC ACID AND VANILLIC ACID BASED CATIONIC LIPIDS
[French]
LIPIDES CATIONIQUES À BASE D'ACIDE PHTALIQUE ET D'ACIDE VANILLIQUE
Applicants **
SANOFI PASTEUR INC.
Inventors
DASARI, Ramesh
DENG, Hongfeng
KARMAKAR, Saswata
LE, Crystal Si-Chuen
Priority Data
63/715,923
04.11.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3880 | |
| EPO | Filing, Examination, Granting | 15420 | |
| Japan | Filing, Examination, Granting | 2169 | |
| South Korea | Filing, Examination, Granting | 2050 | |
| USA | Filing, Examination, Granting | 7140 |
Total:
30,659
Contact Us
Abstract[English]
The present invention provides lipids of Formula (I) and (II) or subformulae thereof, or pharmaceutically acceptable salts thereof. Said lipids can be useful for the delivery and expression of mRNA and encoded protein, e.g. as a component of liposomal delivery vehicles, and accordingly can be useful for treating various diseases, disorders, and conditions, such as those associated with deficiency of one or more proteins. Compositions comprising lipid compounds of Formulae (I) and (II) and subformulae thereof, and mRNA encoding a peptide or protein may be administered to subjects in need thereof intramuscularly.[French]
La présente invention concerne des lipides de formule (I) et (II) ou de sous-formules associées, ou des sels pharmaceutiquement acceptables de ceux-ci. Lesdits lipides peuvent être utiles pour l'administration et l'expression d'ARNm et de protéine codée, par exemple, en tant que constituant de véhicules d'administration liposomale, et peuvent par conséquent être utiles pour traiter divers maladies, troubles et affections, comme ceux associés à un déficit d'une ou de plusieurs protéines. Les compositions comprenant des composés lipidiques de formules (I) et (II) et de sous-formules associées, et un ARNm codant pour un peptide ou une protéine peuvent être administrées à des sujets en ayant besoin par voie intramusculaire.